Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Arena Pharma soars on deal with United Therapeutics for hypertension drug

      Arena Pharma soars on deal with United Therapeutics for hypertension drug

      Medical Dialogues Bureau17 Nov 2018 9:00 AM IST
      In addition to the upfront payment, Arena's deal with United Therapeutics for its pulmonary arterial hypertension treatment (PAH), ralinepag, will...
      CDSCO invites comments on New Drugs and Clinical Trials Rules, 2018

      CDSCO invites comments on New Drugs and Clinical Trials Rules, 2018

      Medical Dialogues Bureau16 Nov 2018 4:56 PM IST
      New Delhi: Through a recent notification CDSCO has invited stakeholders to submit their views or any objections/ suggestions on the draft New Drugs...
      Will Fortis undergo a Name Change? IHH to decide

      Will Fortis undergo a Name Change? IHH to decide

      Medical Dialogues Bureau16 Nov 2018 2:47 PM IST
      “Our most optimistic target is that by the middle of December we will put up the offer and we are cautiously optimistic that by end of December we can...
      Lupin gets USFDA nod for Decitabine- Myelodysplastic Syndrome drug

      Lupin gets USFDA nod for Decitabine- Myelodysplastic Syndrome drug

      Medical Dialogues Bureau16 Nov 2018 11:30 AM IST
      Mumbai: Pharma major Lupin has recently announced that it has received approval for its Decitabine for Injection, 50 mg/vial, Single-Dose Vial from...
      AstraZeneca Pharma India Q2 net profit dips 67% to Rs 9.13 Crore

      AstraZeneca Pharma India Q2 net profit dips 67% to Rs 9.13 Crore

      Medical Dialogues Bureau16 Nov 2018 10:30 AM IST
      New Delhi: Drug firm AstraZeneca Pharma India has recently reported a 66.65 per cent dip in its net profit to Rs 9.13 crore for the quarter ended...
      Make in Odisha:  government launches Rs 2750 Crore investment in Healthcare

      Make in Odisha: government launches Rs 2750 Crore investment in Healthcare

      Medical Dialogues Bureau16 Nov 2018 10:00 AM IST
      New Delhi: Odisha government has launched the Vision-2025 health care at the Make in Odisha Conclave 2018, the flagship biennial global investors'...
      Merck cancer drug Keytruda succeeds in late-stage trial

      Merck cancer drug Keytruda succeeds in late-stage trial

      Medical Dialogues Bureau16 Nov 2018 9:45 AM IST
      New Delhi: U.S Drugmaker Merck & Co has recently announced that blockbuster cancer drug keytruda met the main goal of a late-stage trial, of...
      Walmart, Home Depot adopt health insurer tactic in drug copay battle

      Walmart, Home Depot adopt health insurer tactic in drug copay battle

      Medical Dialogues Bureau16 Nov 2018 9:00 AM IST
      NEW YORK: Walmart and Home Depot, two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using...
      Apollo Hospitals to divest front-end pharmacy business for lumpsum Rs 527.8 crore

      Apollo Hospitals to divest front-end pharmacy business for lumpsum Rs 527.8 crore

      Medical Dialogues Bureau15 Nov 2018 1:35 PM IST
      Under the new structure, AHEL will be the exclusive supplier for APL under a long-term supplier agreement, and AHEL will enter into a brand licencing...
      Pfizer loses blockbuster Epilepsy drug patent fight in UK Supreme Court

      Pfizer loses blockbuster Epilepsy drug patent fight in UK Supreme Court

      Medical Dialogues Bureau15 Nov 2018 11:42 AM IST
      The expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut-price versions of Pfizer's medicine, which...
      Suven Life Sciences gets Product Patents in Australia and Hong Kong

      Suven Life Sciences gets Product Patents in Australia and Hong Kong

      Medical Dialogues Bureau15 Nov 2018 11:30 AM IST
      Hyderabad: Suven Life Science Ltd has recently announced that the grant of one product patent from Australia and one product patent from Hong Kong...
      Zydus gets USFDA nod for Arsenic Trioxide Injection

      Zydus gets USFDA nod for Arsenic Trioxide Injection

      Medical Dialogues Bureau15 Nov 2018 11:05 AM IST
      New Delhi: Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok